NR1H4 and metabolic dysfunction-associated steatohepatitis: It is a 3-fold more potent FXR agonist than OCA (EC50 30 nM vs. 99 nM) and has shown antifibrotic effects in hepatic cell culture models20 and in diet-induced mouse models of MASH.21